Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pheochromocytoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hyperaldosteronism 1Endocrine Gland Neoplasms 1Congenital Abnormalities 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1ACTH Syndrome, Ectopic 1

Interventions

3-Iodobenzylguanidine 8anlotinib 4Temozolomide 4lutetium Lu 177 dotatate 3Phenoxybenzamine 3Everolimus 3pegfilgrastim 2cabozantinib 2Granulocyte Colony-Stimulating Factor 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Adrenalectomy 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1pentetreotide 1penpulimab 1pembrolizumab 1olaparib 1lenvatinib 1lanreotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pheochromocytoma × Staining and Labeling × Clear all
NCT05446779 2024-04-16

SuddenDeath

Helsinki University Central Hospital

Active not recruiting
400 enrolled
Endocrine

ACTH Syndrome, Ectopic, Endocrine Gland Neoplasms, Hyperaldosteronism, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡